World Prematurity Day is observed on 17 November each year to raise awareness of preterm birth, and the concerns of preterm babies and their families worldwide. Approximately 15 million babies are born preterm each year, accounting for about one in 10 of all babies born. For preterm babies who survive, the additional burden of prematurity-related disability and chronic diseases has a long-term affect on families and healthcare systems.
SIME Dx has developed the world’s first rapid lung maturity test, to help Neonatologists preventatively treat the leading cause of morbidity and mortality in premature babies - neonatal Respiratory Distress Syndrome (RDS). To help bring more attention and urgency to preterm birth, and the life threatening diseases associated with it, we have created an infographic highlighting the facts of this global health crisis. VIEW INFOGRAPHIC
SIME Dx today announced that the European Patent Office intends to grant patent number 14727196.9 (“Methods and system for use in neonatal diagnostics”), in recognition of the company's unique method for determining lung maturity at the point-of-care.
At SIME Diagnostics we are developing a digital platform that can measure multiple biomarkers, from a single fluid sample, at the point of care. Our platform is reagent-free and combines a device, machine learning algorithms, and cloud computing, to deliver test results with speed and precision. The technology is supported by medical trials, a strong IP portfolio, and an experienced team. The platform can be used in a wide range of medical areas, but we are starting with an acute unmet need: providing improved care for millions of premature babies through a rapid lung maturity test.
Read full article
LONDON, August 15, 2018 /PRNewswire/ -- Device fully automates neonatal Lung Maturity Test (LMT), representing a major milestone achievement and putting LMT on track for final clinical validation and commercialisation.
The report tracks the world’s most disruptive businesses, compiled and curated by the world’s leading entrepreneurs, investors and business people. Each Disrupt 100 venture was sourced from over 5M global startups and corporate ventures, has been scored against a specific criteria measuring the potential it has to affect an existing market or geography, introduce new customers into an existing market and/or creating a new market with significant customer demand.
LONDON, Jan. 11, 2018 /PRNewswire/ -- SIME Dx, a digital molecular medicine company developing point-of-care diagnostics, has announced the completion of a 2 year EU Horizon 2020 project. The project has significantly accelerated company progress, culminating in the publication of clinical data validating a rapid Lung Maturity Test (LMT), an engineering prototype and new IP. The €2.86 million funding enabled SIME Dx to overcome technical challenges, and prepared the company for further clinical trials, regulatory approval, commercialisation and expansion into China.
In December of 2016, Microsoft UK published a feature article about SIME Dx's bedside test, and the potential it had to "improve the lives of millions of premature babies." The feature was amongst the best-read articles of the year and, therefore, was highlighted as one of the 10 biggest UK stories of 2017.
Recently Published European Consensus Guidelines Highlight the Need for a Bedside Test. LONDON--(BUSINESS WIRE)--SIME Dx, a digital molecular medicine company developing point-of-care diagnostics, announced data validating the efficacy of a lung maturity test (LMT) in identifying infants at risk of respiratory distress syndrome (RDS) who could benefit from early surfactant treatment.